Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation

Liver Transplantation

Volumn 19, Issue 9, 2013, Pages 973-980

  O'Leary, Jacqueline G ^a   Kaneku, Hugo ^b   Jennings, Linda W ^a   Bañuelos, Nubia ^c   Susskind, Brian M ^a   Terasaki, Paul I ^b,c   Klintmalm, Göran B ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TERASAKI FOUNDATION LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACLIZUMAB; DONOR SPECIFIC ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LEUKOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; FEMALE; FLUORESCENCE; GRAFT RECIPIENT; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY DIAGNOSIS; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL;

ADULT; ANTIBODIES; COHORT STUDIES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY ANTIGENS CLASS II; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOGLOBULIN G; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK; TIME FACTORS; TISSUE DONORS; TREATMENT OUTCOME;

EID: 84883229905     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23687     Document Type: Article

References (38)

1. Gordon RD, Fung JJ, Markus B, Fox I, Iwatsuki S, Esquivel CO, et al. The antibody crossmatch in liver transplantation. Surgery 1986; 100: 705-715.
2. Takaya S, Duquesnoy R, Iwaki Y, Demetris J, Yagihashi A, Bronsther O, et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc 1991; 23 (pt 1): 396-399.
3. Ogura K, Koyama H, Takemoto S, Terasaki PI, Busuttil RW,. Significance of a positive crossmatch on outcome in human liver transplantation. Transplant Proc 1992; 24: 1465.
4. Mañez R, Kobayashi M, Takaya S, Bronsther O, Kramer D, Bonet H, et al. Humoral rejection associated with antidonor lymphocytotoxic antibodies following liver transplantation. Transplant Proc 1993; 25 (pt 2): 888-890.
5. Nakamura K, Yagihashi A, Iwaki Y, Takaya S, Hartman GG, Murase N, et al. The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. Transplant Proc 1991; 23: 3021-3022.
6. Demetris AJ, Nakamura K, Yagihashi A, Iwaki Y, Takaya S, Hartman GG, et al. A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 1992; 16: 671-681.
7. Batts KP, Moore SB, Perkins JD, Wiesner RH, Grambsch PM, Krom RA,. Influence of positive lymphocyte crossmatch and HLA mismatching on vanishing bile duct syndrome in human liver allografts. Transplantation 1988; 45: 376-379.
8. Ludwig J, Wiesner RH, Batts KP, Perkins JD, Krom RA,. The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation. Hepatology 1987; 7: 476-483.
9. Takaya S, Bronsther O, Iwaki Y, Nakamura K, Abu-Elmagd K, Yagihashi A, et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation 1992; 53: 400-406.
10. Starzl TE, Demetris AJ, Todo S, Kang Y, Tzakis A, Duquesnoy R, et al. Evidence for hyperacute rejection of human liver grafts: the case of the canary kidneys. Clin Transplant 1989; 3: 37-45.
11. Watson R, Kozlowski T, Nickeleit V, Woosley JT, Schmitz JL, Zacks SL, et al. Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation. Am J Transplant 2006; 6: 3022-3029.
12. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, Egawa H, Yurugi K, Masuda S, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012; 18: 1333-1342.
13. Kaneku H, O'Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB,. Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012; 18: 984-992.
14. Goh A, Scalamogna M, De Feo T, Poli F, Terasaki PI,. Human leukocyte antigen crossmatch testing is important for liver retransplantation. Liver Transpl 2010; 16: 308-313.
15. Kozlowski T, Andreoni K, Schmitz J, Hayashi PH, Nickeleit V,. Sinusoidal C4d deposits in liver allografts indicate an antibody-mediated response: diagnostic considerations in the evaluation of liver allografts. Liver Transpl 2012; 18: 641-658.
16. Kozlowski T, Rubinas T, Nickeleit V, Woosley J, Schmitz J, Collins D, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011; 17: 357-368.
17. O'Leary JG, Kaneku H, Susskind BM, Jennings LW, Neri MA, Davis GL, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011; 11: 1868-1876.
18. Musat AI, Agni RM, Wai PY, Pirsch JD, Lorentzen DF, Powell A, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500-510.
19. Castillo-Rama M, Castro MJ, Bernardo I, Meneu-Diaz JC, Elola-Olaso AM, Calleja-Antolin SM, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554-562.
20. Taner T, Gandhi MJ, Sanderson SO, Poterucha CR, De Goey SR, Stegall MD, Heimbach JK,. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12: 1504-1510.
21. Feng S, Ekong UD, Lobritto SJ, Demetris AJ, Roberts JP, Rosenthal P, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012; 307: 283-293.
22. Mañez R, Kelly RH, Kobayashi M, Takaya S, Bronsther O, Kramer D, et al. Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance. Hepatology 1995; 21: 1345-1352.
23. Scornik JC, Soldevilla-Pico C, Van der Werf WJ, Hemming AW, Reed AI, Langham MR Jr, Howard RJ,. Susceptibility of liver allografts to high or low concentrations of preformed antibodies as measured by flow cytometry. Am J Transplant 2001; 1: 152-156.
24. Gloor JM, Winters JL, Cornell LD, Fix LA, DeGoey SR, Knauer RM, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10: 582-589.
25. Burns JM, Cornell LD, Perry DK, Pollinger HS, Gloor JM, Kremers WK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8: 2684-2694.
26. O'Leary JG, Gebel HM, Ruiz R, Bray RA, Marr JD, Zhou XJ, et al. Class II alloantibody and mortality in simultaneous liver-kidney transplantation. Am J Transplant 2013; 13: 954-960.
27. Dar W, Agarwal A, Watkins C, Gebel HM, Bray RA, Kokko KE, et al. Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants. Am J Transplant 2011; 11: 841-847.
28. Olausson M, Mjörnstedt L, Nordén G, Rydberg L, Mölne J, Bäckman L, Friman S,. Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross-match positive recipients. Am J Transplant 2007; 7: 130-136.
29. Demetris AJ, Murase N, Nakamura K, Iwaki Y, Yagihashi A, Valdivia L, et al. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Semin Liver Dis 1992; 12: 51-59.
30. Donaldson PT, Alexander GJ, O'Grady J, Neuberger J, Portmann B, Thick M, et al. Evidence for an immune response to HLA class I antigens in the vanishing-bileduct syndrome after liver transplantation. Lancet 1987; 1: 945-951.
31. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O,. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966; 2: 662-665.
32. Williams GM, Hume DM, Hudson RP Jr, Morris PJ, Kano K, Milgrom F,. "Hyperacute" renal-homograft rejection in man. N Engl J Med 1968; 279: 611-618.
33. Weil R III, Clarke DR, Iwaki Y, Porter KA, Koep LJ, Paton BC, et al. Hyperacute rejection of a transplanted human heart. Transplantation 1981; 32: 71-72.
34. Hirohashi T, Chase CM, Della Pelle P, Sebastian D, Alessandrini A, Madsen JC, et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 2012; 12: 313-321.
35. Reed EF,. Mechanisms of action and effects of antibodies on the cells of the allograft. Hum Immunol 2012; 73: 1211-1212.
36. Kaneku H, O'Leary JG, Banuelos N, Jennings LW, Susskind BM, Klintmalm GB, Terasaki PI,. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013; 13: 1541-1548.
37. Moonka DK, Kim D, Kapke A, Brown KA, Yoshida A,. The influence of induction therapy on graft and patient survival in patients with and without hepatitis C after liver transplantation. Am J Transplant 2010; 10: 590-601.
38. Cai J, Qing X, Tan J, Terasaki PI,. Humoral theory of transplantation: some hot topics. Br Med Bull 2013; 105: 139-155.